CytomX Therapeutics (CTMX) Research & Development (2016 - 2025)
Historic Research & Development for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $15.3 million.
- CytomX Therapeutics' Research & Development fell 2837.89% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.3 million, marking a year-over-year decrease of 2920.5%. This contributed to the annual value of $83.4 million for FY2024, which is 734.04% up from last year.
- Latest data reveals that CytomX Therapeutics reported Research & Development of $15.3 million as of Q3 2025, which was down 2837.89% from $13.3 million recorded in Q2 2025.
- Over the past 5 years, CytomX Therapeutics' Research & Development peaked at $36.6 million during Q4 2021, and registered a low of $13.3 million during Q2 2025.
- In the last 5 years, CytomX Therapeutics' Research & Development had a median value of $21.4 million in 2024 and averaged $22.9 million.
- Examining YoY changes over the last 5 years, CytomX Therapeutics' Research & Development showed a top increase of 6621.98% in 2021 and a maximum decrease of 4774.84% in 2021.
- CytomX Therapeutics' Research & Development (Quarter) stood at $36.6 million in 2021, then crashed by 46.52% to $19.6 million in 2022, then dropped by 0.91% to $19.4 million in 2023, then dropped by 23.71% to $14.8 million in 2024, then increased by 3.48% to $15.3 million in 2025.
- Its Research & Development stands at $15.3 million for Q3 2025, versus $13.3 million for Q2 2025 and $18.9 million for Q1 2025.